Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP

Ophthalmic Surg Lasers Imaging Retina. 2020 Mar 1;51(3):180-186. doi: 10.3928/23258160-20200228-07.

Abstract

Background and objective: To compare morphologic and functional status at age 4 years for patients treated in one eye with laser photocoagulation and the other eye with intravitreal bevacizumab (IVB) injection for Type 1 retinopathy of prematurity (ROP).

Patients and methods: In this single-center, randomized, controlled trial, best-corrected visual acuity (BCVA) in logMAR was obtained along with spherical equivalent refraction (SER), fluorescein angiography (FA), optical coherent tomography (OCT), and OCT angiography (OCTA).

Results: Eighteen babies (36 eyes) were selected for this study. BCVA and SER were similar in the two groups, but six patients had anisometropia of 4 diopters or more. IVB-treated eyes tended to have thinner foveal thickness than laser-treated eyes (mean difference: -5.33 pixels; 95% confidence interval, -9.62 to -1.05).

Conclusion: Although the differences found here are minimal between the IVB-treated and laser-treated groups, further long-term evaluation of not only FA, but also OCT and OCTA, are needed in larger studies. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:180-186.].

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Bevacizumab / administration & dosage*
  • Female
  • Follow-Up Studies
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Intravitreal Injections
  • Laser Coagulation / methods*
  • Male
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Retina / pathology*
  • Retinopathy of Prematurity / diagnosis*
  • Retinopathy of Prematurity / therapy
  • Retrospective Studies
  • Time Factors
  • Tomography, Optical Coherence / methods
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor